Drug conjugates with polyglycerols
Simple SummaryContent extracted from patent full text and abstract with AI.
The patent describes a drug-polymer conjugate consisting of a branched (dendritic) polyglycerol core surrounded by a polyethylene glycol (PEG) shell, to which one or more pharmaceutically or diagnostically active compounds are attached, often via cleavable linkers. This structure is engineered to improve the delivery, selectivity, and effectiveness of drugs (such as chemotherapy agents), while reducing their toxicity and side effects by improving targeted delivery and release.
Use CasesContent extracted from patent full text and abstract with AI.
- Targeted delivery of chemotherapy drugs for cancer treatment
- Delivery of immunosuppressive, anti-inflammatory, or antiviral drugs for autoimmune and infectious diseases
- Carrying diagnostic agents (such as imaging contrast agents or radionuclides) for enhanced medical imaging or diagnostic applications
- Simultaneous delivery of multiple drugs for combination therapy
- Development of prodrugs with controlled and site-specific release profiles
- Personalized treatment regimens for various complex diseases
BenefitsContent extracted from patent full text and abstract with AI.
- Enhanced targeting and accumulation of drugs at the site of disease (e.g., tumor), minimizing exposure to healthy tissues
- Reduced side effects and toxicity due to controlled and site-specific drug release
- Increased water solubility and biocompatibility of drugs
- Potential for higher drug loading (multiple drugs on one carrier) and combination therapies
- Versatile platform allowing binding of different types of drugs or diagnostic agents
- PEG shell helps evade immune detection, improving circulation time and efficacy
Technical Classifications (CPCs)
Main Classifications
Health, Food & Consumer Tech
Sub Classifications
Medical & Vet Science
CPC Codes
Inventors & Applicants
Inventors
N/A
Applicants
Univ Berlin Freie
Ktb Tumorforschungs Gmbh
Patent Abstract
The present invention relates to a drug polymer conjugate comprising a pharmaceutically and/or diagnostically active compound bound to a dendritic polyglycerol core having a polyethylene glycol shell.
Key Information
Publication No.
EP2216049A1
Family ID
40612968
Publication Date
2010-08-11
Application No.
EP09001693A
Application Date
2009-02-06
Priority Date
2009-02-06
Granted
No
Possible Cooperation
For further information please contact the transfer office.